Classification of heart failure in population based research: An assessment of six heart failure scores Article DOI:
Cite this article as: Mosaterd, A., Deckers, J.W., Hoes, A.W. et al. Eur J Epidemiol (1997) 13: 491. doi:10.1023/A:1007383914444 Abstract
Several scores based on symptoms and signs have been developed to assess the presence of heart failure. The goal of this study was to compare six heart failure scores in non-hospitalised subjects and to determine their usefulness in population based research. The scores were applied to 54 participants of a population based study. All underwent a complete medical examination, including chest X-ray, electrocardiography and Doppler echocardiography. Using all information available, a cardiologist, unaware of the results of the scores, clinically classified participants as having no, possible or definite heart failure. Sensitivity, specificity, predictive values and receiver operating characteristics were calculated, using the cardiologist's assessment as a gold standard. The cardiologist judged definite or possible heart failure to be present in 17 persons. All scores had a high sensitivity for the detection of definite heart failure, whereas the study of men born in 1913 and Walma's score had the highest sensitivity for the combination of possible and definite heart failure. Gheorgiade's and the Boston score had the highest positive predictive values. In conclusion, five of the six scores we studied are broadly similar in the detection of heart failure. The men born in 1913 score relies heavily on the assessment of dyspnea, resulting in a relatively large number of false positives. Although the scores are useful in detecting manifest heart failure, objective measurements of cardiac function appear necessary to reduce the false positive rate and accurately detect early stages of heart failure.
Classification Epidemiology Heart failure Predictive value Sensitivity Specificity References
Ho KK, Pinsky JL, Kannel WB, Levy D. The epidemiology of heart failure: The Framingham Study. J Am Coll Cardiol 1993; 22: 6A-13A.
Bonneux L, Barendregt JJ, Meeter K, Bonsel GJ, van der Maas PJ. Estimating clinical morbidity due to ischemic heart disease and congestive heart failure: The future rise of heart failure. Am J Public Health 1994; 84: 20–28.
Lenfant C. Report of the task force on research in heart failure. Circulation 1994; 90: 1118–1123.
Ho KK, Anderson KM, Kannel WB, Grossman W, Levy D. Survival after the onset of congestive heart failure in Framingham Heart Study subjects. Circulation 1993; 88: 107–115.
Rodeheffer RJ, Jacobsen SJ, Gersh BJ, et al. The incidence and prevalence of congestive heart failure in Rochester, Minnesota. Mayo Clin Proc 1993; 68: 1143–1150.
Packer M. Pathophysiology of chronic heart failure. Lancet 1992; 340: 88–92.
Denolin H, Kuhn H, Krayenbuehl H, Loogen F, Reale A. The definition of heart failure. Eur Heart J 1983; 4: 445–448.
Hlatky MA, Fleg JL, Hinton PC, et al. Physician practice in the management of congestive heart failure. J Am Coll Cardiol 1986; 8: 966–970.
Marantz PR, Alderman MH, Tobin JN. Diagnostic heterogeneity in clinical trials for congestive heart failure. Ann Intern Med 1988; 109: 55–61.
Guyatt GH. Methodologic problems in clinical trials in heart failure. J Chronic Dis 1985; 38: 353–363.
Chakko S, Gheorghiade M. Estimating severity of chronic heart failure: A clinical challenge for the 1990s. Am Heart J 1992; 124: 260–264.
McKee PA, Castelli WP, McNamara PM, Kannel WB. The natural history of congestive heart failure: The Framingham Study. N Engl J Med 1971; 285: 1441–1446.
Wilhelmsen L, Eriksson H, Svardsudd K, Caidahl K. Improving the detection and diagnosis of congestive heart failure. Eur Heart J 1989; 10(suppl C): 13–18.
Gheorghiade M, Beller GA. Effects of discontinuing maintenance digoxin therapy in patients with ischemic heart disease and congestive heart failure in sinus rhythm. Am J Cardiol 1983; 51: 1243–1250.
Carlson KJ, Lee DC, Goroll AH, Leahy M, Johnson RA. An analysis of physicians' reasons for prescribing long-term digitalis therapy in outpatients. J Chronic Dis 1985; 38: 733–739.
Schocken DD, Arrieta MI, Leaverton PE, Ross EA. Prevalence and mortality rate of congestive heart failure in the United States. J Am Coll Cardiol 1992; 20: 301–306.
Walma EP, Hoes AW, Prins A, Boukes FS, van der Does E. Withdrawing long-term diuretic therapy in the elderly: A study in general practice in the Netherlands. Fam Med 1993; 25: 661–664.
Lee DC, Johnson RA, Bingham JB, et al. Heart failure in outpatients: a randomized trial of digoxin versus placebo. N Engl J Med 1982; 306: 699–705.
Hofman A, Grobbee DE, de Jong PT, van den Ouweland FA. Determinants of disease and disability in the elderly: The Rotterdam Elderly Study. Eur J Epidemiol 1991; 7: 403–422.
Remes J, Miettinen H, Reunanen A, Pyorala K. Validity of clinical diagnosis of heart failure in primary health care. Eur Heart J 1991; 12: 315–321.
Rose GA, Blackburn H. Cardiovascular survey methods. Geneva: WHO, 1968.
Willems JL, Abreu-Lima C, Arnaud P, et al. The diagnostic performance of computer programs for the interpretation of electrocardiograms. N Engl J Med 1991; 325: 1767–1773.
Sahn DJ, DeMaria A, Kisslo J, Weyman A. Recommendations regarding quantication in M-mode echocardiography: Results of a survey of echocardiographic measurements. Circulation 1978; 58: 1072–1083.
The Criteria Committee of the New York Heart Association. Diseases of the heart and blood vessels, 6th ed. Boston: Little, Brown & Co. 1995.
Altman DG. Practical statistics for medical research. London: Chapman & Hall, 1993.
Hanley JA, McNeil BJ. The meaning and use of the area under a receiver operating characteristic (ROC) curve. Radiology 1982; 143: 29–36.
Hanley JA, McNeil BJ. A method of comparing the areas under receiver operating characteristic curves derived from the same cases. Radiology 1983; 148: 839–843.
The Task Force on Heart Failure of the European Society of Cardiology. Guidelines for the diagnosis of heart failure. Eur Heart J 1995; 16: 741–751.
The CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure: Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med 1987; 316: 1429–35.
Anonymous. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators. Lancet 1993; 342: 821–828.
The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991; 325: 293–302.
Goldman L, Hashimoto B, Cook EF, Loscalzo A. Comparative reproducibility and validity of systems for assessing cardiovascular functional class: Advantages of a new specific activity scale. Circulation 1981; 64: 1227–1234.
Gaasch WH. Diagnosis and treatment of heart failure based on left ventricular systolic or diastolic dysfunction. JAMA 1994; 271: 1276–1280.
Bonow RO, Udelson JE. Left ventricular diastolic dysfunction as a cause of congestive heart failure. Mechanisms and management. Ann Intern Med 1992; 117: 502–510.
Vasan RS, Benjamin EJ, Levy D. Prevalence, clinical features and prognosis of diastolic heart failure: An epidemiologic perspective. J Am Coll Cardiol 1995; 26: 1565–1574.
McCall D. Recognition and management of asymptomatic patients with left ventricular dysfunction. Am J Cardiol 1992; 69: 130G-139G.
The SOLVD Investigators. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med 1992; 327: 685–691.
Pfeffer MA, Braunwald E, Moye LA, et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. N Engl J Med 1992; 327: 669–677.
Marantz PR, Tobin JN, Wassertheil-Smoller S, et al. The relationship between left ventricular systolic function and congestive heart failure diagnosed by clinical criteria. Circulation 1988; 77: 607–612.
Eriksson H, Svardsudd K, Caidahl K, et al. Early heart failure in the population. The study of men born in 1913. Acta Med Scand 1988; 223: 197–209.
Eriksson H, Caidahl K, Larsson B, et al. Cardiac and pulmonary causes of dyspnoea — validation of a scoring test for clinical-epidemiological use: The Study of Men Born in 1913. Eur Heart J 1987; 8: 1007–1014.
Mosterd A. Epidemiology of heart failure. Thesis. Rotterdam, 1997.
Dargie HJ, McMurray JJ. Diagnosis and management of heart failure. Br Med J 1994; 308: 321–328.
Goldsmith SR, Dick C. Differentiating systolic from diastolic heart failure: Pathophysiologic and therapeutic considerations. Am J Med 1993; 95: 645–655.
Wheeldon NM, Clarkson P, MacDonald TM. Diastolic heart failure. Eur Heart J 1994; 15: 1689–1697.
Lerman A, Gibbons RJ, Rodeheffer RJ, et al. Circulating N-terminal atrial natriuretic peptide as a marker for symptomless left-ventricular dysfunction. Lancet 1993; 341: 1105–1109.
Benedict CR. Neurohumoral aspects of heart failure. Cardiol Clin 1994; 12: 9–23.
Armstrong PW, Moe GW. Medical advances in the treatment of congestive heart failure. Circulation 1993; 88: 2941–2952.
Garg R, Yusuf S. Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. JAMA 1995; 273: 1450–1406.
Google Scholar Copyright information
© Kluwer Academic Publishers 1997